Navigating the divergence: A risk-centric framework for simultaneous compliance with the US QMSR, EU MDR, and MDSAP
£59.00
Discover how a risk-centric ‘Master QMS’ framework can streamline simultaneous compliance with the US QMSR, EU MDR and MDSAP while ensuring device safety
English
Abstract:
The global medical device regulatory landscape continues to evolve towards structural harmonisation. However, significant divergence persists in implementation and evidentiary expectations in real-world scenarios. The US Food and Drug Administration (FDA)’s Quality Management System Regulation (QMSR) fundamentally restructures the US quality system framework by incorporating ISO 13485:2016 by reference. While this transition establishes a lifecycle-based, risk-driven quality management foundation, it retains FDA-specific requirements and does not eliminate jurisdictional differences. In parallel, the European Union’s Regulation (EU) 2017/745 on medical devices (EU MDR) introduces more prescriptive and clinically integrated requirements in the areas of clinical evaluation, post-market surveillance (PMS), and post-market clinical follow-up (PMCF). These requirements generally establish an expectation of continuous assessment of clinical and real-world evidence.
Mathangi Srinivasan’s article examines key areas of regulatory divergence across risk management, corrective and preventive action (CAPA) systems, and vigilance reporting frameworks. Emphasis is placed on contrasting risk reduction philosophies, including interpretations aligned with ‘as low as reasonably practicable’ and ‘as far as possible’, as well as the role of ‘state of the art’ in continuous risk reassessment. To address these challenges, a risk-centric ‘Master QMS’ architecture is proposed, leveraging ISO 14971:2019 as a unifying lifecycle framework that integrates design controls, clinical evaluation, and post-market data. This approach enables closed-loop integration across PMS, PMCF, risk management, and CAPA, providing a practical model for achieving simultaneous compliance across the US QMSR, EU MDR, and Medical Device Single Audit Program (MDSAP) while maintaining system efficiency and ensuring sustained device safety and performance.
Learning objectives:
- Understand the regulatory architecture of the US QMSR, EU MDR, and MDSAP, including the role of ISO 13485 and ISO 14971.
- Identify key areas of regulatory divergence between the US QMSR and EU MDR, particularly in relation to risk management, PMS, clinical evidence, and vigilance reporting.
- Critically evaluate the differing approaches to risk reduction and risk acceptability, including the practical implications of benefit-risk assessment and the EU MDR’s ‘as far as possible’ requirements.
- Assess the significance of ‘state of the art’ under the EU MDR and its implications for ongoing risk management and lifecycle compliance.
- Examine how PMS, PMCF, CAPA, clinical evaluation, and risk management can be integrated into a closed-loop QMS.
- Evaluate the role of MDSAP in supporting a process-based, globally integrated QMS across multiple regulatory jurisdictions.
- Apply a risk-centric, ‘highest standard’ approach to the design of a Master QMS capable of supporting simultaneous compliance with divergent regulatory requirements.
About the author:
Mathangi Srinivasan is a Quality Assurance Manager in the medical device industry in California, USA with more than 12 years’ experience in quality and manufacturing. She holds Master’s Degrees in Biochemistry and Industrial Engineering from the University of Wisconsin-Madison, and an MBA from Auburn University. She is an ASQ certified Six Sigma Black Belt (CSSBB) and a Certified Quality Auditor. Her work prioritises building scalable, audit-resilient quality systems that ensure patient safety across international jurisdictions.
Specification:
14 pages plus covers, in English, supplied by email as a PDF.
This article has been published in the November 2026 issue of the Journal of Medical Device Regulation.
